Triple Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI: a Fading Role

@article{Alexopoulos2017TripleAT,
  title={Triple Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI: a Fading Role},
  author={D. Alexopoulos and Panagiotis Vlachakis and J. Lekakis},
  journal={Cardiovascular Drugs and Therapy},
  year={2017},
  volume={31},
  pages={319-324}
}
  • D. Alexopoulos, Panagiotis Vlachakis, J. Lekakis
  • Published 2017
  • Medicine
  • Cardiovascular Drugs and Therapy
  • Triple antithrombotic therapy (TAT), consisting of aspirin, a P2Y12 receptor antagonist and oral anticoagulant (OAC) medication has been considered as an ‘unavoidable’ strategy for a 1–12 months for atrial fibrillation (AF) patients post acute coronary syndrome or percutaneous coronary angioplasty with stenting. However, TAT has rather poorly been adopted in real life practice, mainly because of an accompanying increased bleeding potential and lack of definitive results of randomized clinical… CONTINUE READING

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 48 REFERENCES
    Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).
    • 3,748
    • Highly Influential
    • PDF
    Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI.
    • 732
    • Highly Influential
    • PDF